Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 76Leukemia 66Myelodysplastic Syndromes 56Lymphoma 34Lymphoma, Non-Hodgkin 33Leukemia, Lymphocytic, Chronic, B-Cell 30Hodgkin Disease 27Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Burkitt Lymphoma 25Multiple Myeloma 24Lymphoma, Mantle-Cell 19Lymphoma, Follicular 18Hematologic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Large B-Cell, Diffuse 16Leukemia, Biphenotypic, Acute 16Recurrence 15Myeloproliferative Disorders 15Congenital Abnormalities 15Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Lymphoma, Large-Cell, Immunoblastic 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Blast Crisis 10Graft vs Host Disease 9Neoplasms, Plasma Cell 8Leukemia, Myelomonocytic, Juvenile 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Acute 7

Interventions

fludarabine 3filanesib 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Dexamethasone 2Bortezomib 2Alemtuzumab 2ofatumumab 1fludarabine phosphate 1Zoledronic Acid 1Whole-Body Irradiation 1Stem Cell Transplantation 1Proteasome Inhibitors 1Mycophenolic Acid 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Denosumab 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Paraproteinemias × Granulocyte Colony-Stimulating Factor × Other hematologic neoplasm × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡